PODD

Insulet Corporation

Healthcare
143.30 +0.87 +0.61% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 9.93B
EV —
Shares Out 69.26M
Revenue (ttm) 2.90B
Net Income 302.80M
Beta —
P/E 33.12
Forward P/E —
EPS (ttm) $4.28
P/S 3.46
P/B 7.70
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 10.14%
ROE 21.9%
ROIC 16.87%
Gross Margin 71.01%
Oper. Margin 17.48%
Profit Margin 10.44%
Debt/Eq 0.73
LT Debt/Eq 41.64%
Quick Ratio —
Current Ratio 2.49
Book/sh 18.61
Cash/sh —
Div Yield —
Div TTM —
Payout Ratio —
SMA20 -5.1%
SMA50 -19.64%
SMA200 -46.23%
Volume 1,140,980
Avg Volume 1.24M
Rel Volume —
Perf Week -1.13%
Perf Month -14.46%
Perf Quarter -40.52%
Perf Half Y -52.94%
Perf YTD -49.58%
Perf Year -54.82%
Perf 3Y -49.55%
Perf 5Y -47.29%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Insulet Corporation is primarily engaged in the development, manufacture, and sale of proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod Insulin Management System (Classic Omnipod). Omnipod 5 integrates with continuous glucose monitors from Dexcom and Abbott to automatically adjust insulin dosing and improve time-in-range through an embedded algorithm. Omnipod DASH features a wireless Bluetooth-enabled pod controlled by a smartphone-like Personal Diabetes Manager. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for chemotherapy support. Omnipod products are available in 25 countries globally. The company sells primarily through wholesalers and distribution partners, with 86% of 2025 Omnipod product sales through intermediaries. The company operates highly automated manufacturing facilities in Acton, Massachusetts and Johor, Malaysia, with additional production in China via contract manufacturing and a new facility planned in Costa Rica. As of 2025, the company had more than 600,000 Podders (active users) globally.

Name
Insulet Corporation
Industry
Medical Devices
CEO
Ashley A. McEvoy · President and Chief Executive Officer
Employees
—
IPO Date
2015-05-04
Phone
(978) 600-7000
Address
100 Nagog Park, Acton, MA 01720
Website
—

Key Executives

Name Title FY Pay
Wayne A. I. Frederick Interim President, Howard University —
Timothy C. Stonesifer Chief Financial Officer, Alcon Inc. —
Michael R. Minogue President and Chief Executive Officer, Minogue Consulting, LLC —
Luciana Borio Venture Partner, ARCH Venture Partners —
Ashley A. McEvoy President and Chief Executive Officer —

Latest News